Results 141 to 150 of about 4,565 (192)

Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for <i>ALK-</i>Mutated NSCLC. [PDF]

JTO Clin Res Rep
Munarriz BJ, Khan S, Hueniken K, Tam S, Patel D, Zhan L, Brown C, Eng L, Sacher A, Bradbury P, Leighl N, Liu G, Shepherd FA.   +12 more
europepmc   +1 more source

3D organotypic skin models recapitulate autoantibody-driven pemphigus pathomechanisms and targeted therapeutic response. [PDF]

Sci Adv
Zhai H, Jin X, Moghaddam AO, Spieker MF, Seiffert-Sinha K, Sinha AA, Yang R, Meng F.   +7 more
europepmc   +1 more source

Lorlatinib in ALK-positive non-small cell lung cancer: final survival data that reshape the therapeutic landscape. [PDF]

Transl Lung Cancer Res
Katayama Y.
europepmc   +1 more source

Update on Oral Oncolytics [PDF]

, 2020
Osmon, Elizabeth
core   +1 more source

Effectiveness of First-Line Treatment with Anaplastic Lymphoma Kinase and ROS1 Protoncogene Inhibitors in Non-Small Cell Lung Cancer Patients-Real-World Evidence of Two Polish Cancer Centers. [PDF]

Cancers (Basel)
Gil M, Winiarczyk K, Krawczyk P, Wojas-Krawczyk K, Łomża-Łaba A, Obara A, Gajek Ł, Reszka K, Tysarowski A, Buczkowski J, Chmielewska I, Jankowski T, Szuba-Gil M, Strzemski M, Kowalski DM, Milanowski J, Krzakowski M.   +16 more
europepmc   +1 more source

Optimizing long-term treatment with ALK inhibitors: balancing efficacy and safety. [PDF]

Transl Lung Cancer Res
Dai A, Sasaki T.
europepmc   +1 more source

Tyrosine-kinase inhibitors for lung or breast cancer and drug-drug interactions: a clinical guide. [PDF]

Oncol Rev
Santamaria F, Roberto M, Maltese G, Nicolella F, Torchia A, Buccilli D, Di Civita MA, Giancontieri P, Marinelli D, Cirillo A, Bianco V, Verrico M, Botticelli A, Santini D.   +13 more
europepmc   +1 more source

Lorlatinib atypical safety profile in ALK-positive aNSCLC: tips for management from an Italian expert panel. [PDF]

Future Oncol
Ardizzoni A, Cortinovis D, Gori B, Nuzzo A, Pasello G, de Marinis F.   +5 more
europepmc   +1 more source

Treatment Patterns, Prognostic Factors and Survival for ALK-Positive Advanced NSCLC In Australia: Results From the Australasian Thoracic Cancers Longitudinal Cohort Study and Biobank (AURORA). [PDF]

JTO Clin Res Rep
Chazan G, Alexander M, Franchini F, IJzerman M, Shah R, John A, Spelman T, Itchins M, Pavlakis N, Nagrial A, Warburton L, Bowyer S, Kao S, Parakh S, Solomon BJ.   +14 more
europepmc   +1 more source

Exceptional response to brigatinib following alectinib failure in a patient with <i>ALK</i> fusion-positive duodenal carcinoma. [PDF]

Int Cancer Conf J
Sasaki A, Chihara S, Okamoto R, Yoshino T, Nakamura Y.   +4 more
europepmc   +1 more source